Subtopic Deep Dive
Bevacizumab Colorectal Cancer Therapy
Research Guide
What is Bevacizumab Colorectal Cancer Therapy?
Bevacizumab colorectal cancer therapy uses the anti-VEGF monoclonal antibody bevacizumab combined with chemotherapy as first-line treatment for metastatic colorectal cancer to inhibit tumor angiogenesis and extend patient survival.
Bevacizumab targets vascular endothelial growth factor (VEGF) to block blood vessel formation in tumors. A phase II trial showed bevacizumab added to bolus fluorouracil and leucovorin improved response rates and survival in first-line metastatic CRC (Kabbinavar et al., 2005, 932 citations). ESMO guidelines recommend bevacizumab with chemotherapy for metastatic colorectal cancer management (Van Cutsem et al., 2014, 1174 citations).
Why It Matters
Bevacizumab combined with chemotherapy extends median survival from 12 to over 20 months in metastatic CRC patients, enabling hepatic resection in more cases (Kopetz et al., 2009, 1349 citations). NCCN guidelines integrate bevacizumab into first-line regimens, influencing treatment selection across 32 monotherapies and combinations (Benson et al., 2017, 1354 citations). Targeted therapies like bevacizumab shape sequencing with agents such as cetuximab in KRAS wild-type patients (Amado et al., 2008, 3139 citations).
Key Research Challenges
Hypertension Biomarker Identification
Bevacizumab induces hypertension as a toxicity, requiring biomarkers for risk stratification. No validated predictors exist from phase II trials (Kabbinavar et al., 2005). ESMO guidelines highlight monitoring needs without specific markers (Van Cutsem et al., 2014).
Optimal Chemotherapy Sequencing
Sequencing bevacizumab with FOLFOX or FOLFIRI remains unoptimized for progression-free survival. Trials show improved outcomes with resection adoption but lack direct comparisons (Kopetz et al., 2009). NCCN lists multiple lines without bevacizumab-specific order (Benson et al., 2017).
KRAS Biomarker Integration
Bevacizumab efficacy persists across KRAS statuses, unlike EGFR inhibitors needing wild-type KRAS (Amado et al., 2008, 3139 citations). Comprehensive reviews note challenges combining anti-VEGF with KRAS-targeted strategies (Xie et al., 2020).
Essential Papers
Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Rafael G. Amado, Michael Wolf, Marc Peeters et al. · 2008 · Journal of Clinical Oncology · 3.1K citations
Purpose Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating m...
Immunotherapy in colorectal cancer: rationale, challenges and potential
Karuna Ganesh, Zsofia K. Stadler, Andrea Cercek et al. · 2019 · Nature Reviews Gastroenterology & Hepatology · 1.9K citations
Comprehensive review of targeted therapy for colorectal cancer
Yuanhong Xie, Yingxuan Chen, Jing‐Yuan Fang · 2020 · Signal Transduction and Targeted Therapy · 1.6K citations
Abstract Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and chemotherapy have...
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Inés Mármol, Cristina Sánchez‐de‐Diego, Alberto Pradilla-Dieste et al. · 2017 · International Journal of Molecular Sciences · 1.5K citations
Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related death. Most cases of CRC are detected in Western countries, with its incidence increasing ...
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
Scott Kopetz, Axel Grothey, Rona Yaeger et al. · 2019 · New England Journal of Medicine · 1.4K citations
A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal ca...
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Al B. Benson, Alan P. Venook, Lynette Cederquist et al. · 2017 · Journal of the National Comprehensive Cancer Network · 1.4K citations
This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combin...
Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
Scott Kopetz, George J. Chang, Michael J. Overman et al. · 2009 · Journal of Clinical Oncology · 1.3K citations
Purpose Fluorouracil/leucovorin as the sole therapy for metastatic colorectal cancer (CRC) provides an overall survival of 8 to 12 months. With an increase in surgical resections of metastatic dise...
Reading Guide
Foundational Papers
Start with Kabbinavar et al. (2005, 932 citations) for phase II evidence of bevacizumab survival benefits; follow with Van Cutsem et al. (2014, 1174 citations) ESMO guidelines for clinical integration.
Recent Advances
Study Benson et al. (2017, 1354 citations) NCCN guidelines for bevacizumab in multi-line therapy; Xie et al. (2020, 1589 citations) for targeted therapy context.
Core Methods
Phase II/III randomized trials compare bevacizumab plus chemotherapy (fluorouracil-leucovorin, FOLFOX) vs chemotherapy alone, measuring progression-free survival, response rates, and VEGF inhibition.
How PapersFlow Helps You Research Bevacizumab Colorectal Cancer Therapy
Discover & Search
PapersFlow's Research Agent uses searchPapers with 'bevacizumab first-line metastatic colorectal cancer' to retrieve Kabbinavar et al. (2005) phase II trial (932 citations), then citationGraph maps connections to Van Cutsem et al. (2014) ESMO guidelines and findSimilarPapers identifies bevacizumab sequencing studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival data from Kabbinavar et al. (2005), then runPythonAnalysis with pandas computes meta-analysis of response rates across trials, verified by verifyResponse (CoVe) and GRADE grading for evidence quality in bevacizumab hypertension risks.
Synthesize & Write
Synthesis Agent detects gaps in bevacizumab-KRAS integration from Amado et al. (2008), flags contradictions with Xie et al. (2020), while Writing Agent uses latexEditText, latexSyncCitations for Kabbinavar references, and latexCompile generates trial comparison tables with exportMermaid for treatment sequencing diagrams.
Use Cases
"Run survival meta-analysis on bevacizumab + FOLFOX trials in mCRC"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas survival curves from Kabbinavar 2005, Kopetz 2009) → matplotlib hazard ratio plot → GRADE-verified report.
"Draft LaTeX review section on bevacizumab first-line efficacy"
Synthesis Agent → gap detection (Van Cutsem 2014 gaps) → Writing Agent → latexEditText (add Benson 2017 citations) → latexSyncCitations → latexCompile → PDF with ESMO guideline flowchart.
"Find code for bevacizumab response prediction models"
Research Agent → paperExtractUrls (Xie 2020 targeted therapy papers) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis sandbox tests CRC biomarker scripts.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on bevacizumab mCRC, chains citationGraph to Kopetz (2009), and outputs structured report with GRADE-scored survival improvements. DeepScan applies 7-step CoVe analysis to Kabbinavar (2005) abstracts, verifying hypertension data against NCCN (Benson 2017). Theorizer generates hypotheses on bevacizumab sequencing from Amado (2008) KRAS data.
Frequently Asked Questions
What defines bevacizumab colorectal cancer therapy?
Bevacizumab is an anti-VEGF antibody combined with first-line chemotherapy like fluorouracil-leucovorin for metastatic CRC to inhibit angiogenesis (Kabbinavar et al., 2005).
What methods prove bevacizumab efficacy?
Randomized phase II trial showed bevacizumab plus bolus fluorouracil-leucovorin improved response (23% vs 11%) and survival in mCRC (Kabbinavar et al., 2005, 932 citations). ESMO endorses it in guidelines (Van Cutsem et al., 2014).
What are key papers on bevacizumab in CRC?
Kabbinavar et al. (2005, 932 citations) reports phase II results; Kopetz et al. (2009, 1349 citations) links it to resection survival gains; Benson et al. (2017, 1354 citations) in NCCN guidelines.
What open problems exist in bevacizumab therapy?
Optimal sequencing with irinotecan or oxaliplatin lacks direct trials; hypertension biomarkers absent (Kabbinavar et al., 2005); KRAS-independent efficacy needs combination strategies (Amado et al., 2008).
Research Colorectal Cancer Treatments and Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Bevacizumab Colorectal Cancer Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers